Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research (R01 Clinical Trial Optional)
Grant Opportunity Analysis
The National Institutes of Health (NIH), through the National Library of Medicine (NLM), has announced a funding opportunity titled "Advancing Bioinformatics, Translational Bioinformatics, and Computational Biology Research (R01 Clinical Trial Optional)." This grant aims to support innovative research projects that develop advanced methods, tools, and approaches to enhance biomedical data science, particularly leveraging technologies such as artificial intelligence and machine learning to extract actionable insights from complex biological datasets. The initiative is crucial for improving health outcomes by facilitating the interpretation and integration of multi-dimensional biological data. Interested applicants can submit proposals until March 5, 2029, with a maximum funding amount of $250,000 per year and an estimated total program funding of $2,500,000 for approximately 10 awards. For further inquiries, applicants may contact the NLM at NLMProgram@nih.gov.
Eligible Applicants
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. This new requirement was effective, May 1, 2025.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.